We are live on ! Find out more
PVLA

Palvella Therapeutics
PVLA

105 hedge funds and large institutions have $199M invested in Palvella Therapeutics in 2018 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 38 increasing their positions, 29 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

31% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 29

11% more capital invested

Capital invested by funds: $179M → $199M (+$20.4M)

0.01% more ownership

Funds ownership: 0.82% → 0.82% (+0.01%)

9% less funds holding

Funds holding: 115 → 105 (-10)

45% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 22

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $363K

Holders
105
Holders Change
-10
Holders Change %
-8.7%
% of All Funds
2.4%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.07%
New
12
Increased
38
Reduced
29
Closed
22
Calls
–
Puts
$363K
Net Calls
-$363K
Net Calls Change
+$122K

Top Buyers

1
NCM
Nantahala Capital Management
Connecticut
+$3.45M
2
Millennium Management
Millennium Management
New York
+$3.38M
3
PM
Prosight Management
Texas
+$1.64M
4
BI
BVF Inc
California
+$1.38M
5
PAWC
P.A.W. Capital
Connecticut
+$1.36M

Top Sellers

1
O
OrbiMed
New York
-$3.72M
2
SSA
Schonfeld Strategic Advisors
New York
-$2.33M
3
OAM
Oxford Asset Management
United Kingdom
-$1.26M
4
BIM
Bogle Investment Management
Massachusetts
-$904K
5
LOAMU
Lombard Odier Asset Management (USA)
New York
-$857K
Name Holding Trade Value Shares
Change 		Change in
Stake
PAWC
26
P.A.W. Capital
Connecticut
$1.4M +$1.36M +3,125 New
CWM
27
CIBC World Markets
New York
$1.25M -$148K -341 -11%
Charles Schwab
28
Charles Schwab
California
$1.2M – – –
Citadel Advisors
29
Citadel Advisors
Florida
$1.08M +$651K +1,499 +163%
PIM
30
Platinum Investment Management
Australia
$1.08M +$369K +848 +55%
Cerity Partners
31
Cerity Partners
New York
$1.07M – – –
Allianz Asset Management
32
Allianz Asset Management
Germany
$1.04M +$80K +184 +9%
BIM
33
Bogle Investment Management
Massachusetts
$939K -$904K -2,081 -50%
Baird Financial Group
34
Baird Financial Group
Wisconsin
$933K +$7.39K +17 +0.8%
Marshall Wace
35
Marshall Wace
United Kingdom
$902K +$748K +1,721 +589%
FQ
36
First Quadrant
California
$880K -$493K -1,135 -37%
FDCDDQ
37
Federation des caisses Desjardins du Quebec
Quebec, Canada
$870K – – –
OAM
38
Oxford Asset Management
United Kingdom
$831K -$1.26M -2,890 -61%
Deutsche Bank
39
Deutsche Bank
Germany
$828K +$204K +469 +34%
AllianceBernstein
40
AllianceBernstein
Tennessee
$814K +$20.9K +48 +3%
Assenagon Asset Management
41
Assenagon Asset Management
Luxembourg
$808K -$217K -500 -22%
AQR Capital Management
42
AQR Capital Management
Connecticut
$775K -$349K -803 -32%
SIM
43
Spark Investment Management
New York
$771K -$260K -599 -26%
Morgan Stanley
44
Morgan Stanley
New York
$727K +$19.6K +45 +3%
Two Sigma Advisers
45
Two Sigma Advisers
New York
$678K +$17.4K +40 +3%
Bank of New York Mellon
46
Bank of New York Mellon
New York
$638K +$29.1K +67 +5%
SO
47
STRS Ohio
Ohio
$588K – – –
AIM
48
Assured Investment Management
New York
$530K -$21.7K -50 -4%
Creative Planning
49
Creative Planning
Kansas
$499K – – –
VEA
50
Virtus ETF Advisers
New York
$498K -$345K -795 -42%
1
2
3 4 5

PVLA Hedge Fund Activity: Q3 2018 in Review

105 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q3 2018, worth a combined $199M — up 11% from $179M a quarter earlier.

Sellers outnumbered buyers: 22 funds closed out of PVLA and 12 opened new positions — a net loss of 10 holders — while 29 trimmed existing stakes and 38 added.

The largest buyer was Nantahala Capital Management, opening a new position worth an estimated $3.45M. The largest seller was OrbiMed, cutting an estimated $3.72M.

  • 105 institutional investors held Palvella Therapeutics (PVLA) as of Q3 2018, down from 115 in Q2 2018.
  • Funds reported $199M of Palvella Therapeutics stock for Q3 2018, up 11% quarter-over-quarter.
  • 12 funds opened new Palvella Therapeutics positions in Q3 2018 and 22 closed out, a net change of -10 holders.
  • The largest Palvella Therapeutics buyer in Q3 2018 was Nantahala Capital Management, an estimated $3.45M added.
  • The largest Palvella Therapeutics seller in Q3 2018 was OrbiMed, an estimated $3.72M sold.

Based on aggregated 13F filings for Q3 2018.